Arthritis, Psoriatic Clinical Trial
Official title:
A Phase-IV, Multicenter, Noncomparative, Open-Label Study Evaluating the Safety and Efficacy of Golimumab (a Fully Human Anti-TNFα Monoclonal Antibody, Administered Subcutaneously) in the Treatment of Indian Patients With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis
The purpose of this study is to assess the safety of subcutaneous (SC) golimumab in participants with active Ankylosing Spondylitis (AS) or Psoriatic Arthritis (PsA) over 24 weeks.
This post-marketing study will evaluate safety and efficacy profile of golimumab (a fully human anti-Tumour Necrosis Factor alpha [TNF-alpha] monoclonal antibodies [mAb], administered subcutaneously) in a real-world in Indian participants with active spondyloarthropathy of ankylosing spondylitis (AS) or psoriatic arthritis (PsA). AS is a chronic inflammatory disease of unknown etiology that involves the sacroiliac joints, axial skeleton, entheses, and peripheral joints. PsA is a chronic, inflammatory, usually rheumatoid factor negative arthritis that is associated with psoriasis. Golimumab binds with high affinity to human TNF-alpha and inhibits TNF-alpha bioactivity, TNF-alpha-mediated cell cytotoxicity and TNF-alpha mediated endothelial cell activation. Golimumab also induces activation of complement-mediated cell lysis and reduces the development of arthritis. Study evaluation includes efficacy (efficacy parameters for AS and PsA) and safety. Participant's safety will be monitored throughout the study. The total duration of study will be approximately 24 weeks. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02181673 -
A Study of Golimumab in Participants With Active Psoriatic Arthritis
|
Phase 3 | |
| Recruiting |
NCT04936308 -
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
|
Phase 3 | |
| Terminated |
NCT00090129 -
Onercept in the Treatment and Re-Treatment of Subjects With Moderate to Severe Plaque Psoriasis
|
Phase 3 | |
| Withdrawn |
NCT03625089 -
Impact of Nurse-led Programme With Carotid Ultrasound on Addressing Cardiovascular Risk in Patients With Arthritis
|
N/A | |
| Recruiting |
NCT05571696 -
Mind Matters: A High Touch, Low Cost Approach to Improving Mental Health Outcomes in Patients With Psoriatic Diseases
|
N/A | |
| Active, not recruiting |
NCT05071664 -
A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis
|
Phase 2 | |
| Completed |
NCT00938015 -
Study Evaluating Safety and Adherence to Treatment With Etanercept in Adults With Psoriatic Arthritis
|
N/A | |
| Suspended |
NCT03703934 -
Central Pain Mechanisms in Patients With Hand-Osteoarthritis, Psoriatic Arthritis and Healthy Controls
|
||
| Recruiting |
NCT05092269 -
A Long-term Extension Study of Ustekinumab in Pediatric Participants
|
Phase 3 | |
| Terminated |
NCT05083078 -
A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis
|
Phase 1 | |
| Completed |
NCT02436785 -
Do Inflammatory Arthritis Inpatients Receiving Group Music Therapy Improve Pain Compared to Music Listening?
|
N/A | |
| Completed |
NCT02294227 -
16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis
|
Phase 3 | |
| Completed |
NCT00998829 -
Study Evaluating The Prevalence Of Undiagnosed Psoriatic Arthritis In Patients With Plaque Psoriasis
|
N/A | |
| Completed |
NCT00760669 -
An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Participants
|
Phase 4 | |
| Completed |
NCT00367237 -
Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease (RESPOND) (Study P04422)
|
Phase 3 | |
| Completed |
NCT00051623 -
A Study of the Safety and Effectiveness of Infliximab for the Treatment of Psoriatic Arthritis
|
Phase 3 | |
| Withdrawn |
NCT04680676 -
A Study to Test Different Doses of BI 730357 and Find Out Whether They Reduce Symptoms in People With Active Psoriatic Arthritis
|
Phase 2 | |
| Completed |
NCT03008590 -
Low Dose Naltrexone for Chronic Pain From Arthritis
|
Phase 2 | |
| Recruiting |
NCT05657847 -
Novel Complex Radiodiagnostics of Peripherial Arthropathies
|
||
| Completed |
NCT02875184 -
A Study of Apremilast Use and Effectiveness in Patients With Psoriatic Arthritis in The Netherlands
|